ConductScience.org, home

Paper36588676

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae.

Yu Z and 18 others. Front Pharmacol, 2022. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae. Papers, record 36588676. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36588676

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae.
PubMed
Journal
Front Pharmacol
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
3.25
iCite
Revised in PubMed
2023-01-11
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yu ZZhenwei
2Liu XXiaofen
3Du XXiaoxing
4Chen HHuiying
5Zhao FFeng
6Zhou ZZhihui
7Wang YYu
8Zheng YYang
9Bergen PJPhillip J
10Li XXi
11Sun RRenhua
12Fang LLi
13Li WWanzhen
14Fan YYaxin
15Wu HHailan
16Guo BBeining
17Li JJian
18Yu YYunsong
19Zhang JJing

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References61

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129238962Population Pharmacokinetics of Polymyxin B.Clin Pharmacol Ther2018https://conductscience.org/library/papers/29238962PubMed
217890940Pharmacokinetic-pharmacodynamic crisis in the elderly.Am J Ther2007https://conductscience.org/library/papers/17890940PubMed
327998750Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.J Infect2017https://conductscience.org/library/papers/27998750PubMed
423776390Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration.Int J Nephrol Renovasc Dis2013https://conductscience.org/library/papers/23776390PubMed
520573659fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.J Antimicrob Chemother2010https://conductscience.org/library/papers/20573659PubMed
618922815In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae.J Antimicrob Chemother2008https://conductscience.org/library/papers/18922815PubMed
720585118Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.Antimicrob Agents Chemother2010https://conductscience.org/library/papers/20585118PubMed
830950096Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients.Br J Clin Pharmacol2019https://conductscience.org/library/papers/30950096PubMed
930722960Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.Int J Antimicrob Agents2019https://conductscience.org/library/papers/30722960PubMed
1020961911Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia.J Antimicrob Chemother2011https://conductscience.org/library/papers/20961911PubMed
1132052041Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints.Clin Infect Dis2020https://conductscience.org/library/papers/32052041PubMed
1233782834Population Pharmacokinetics of Vixotrigine in Healthy Volunteers and Subjects with Trigeminal Neuralgia, Painful Lumbosacral Radiculopathy and Erythromelalgia.Eur J Drug Metab Pharmacokinet2021https://conductscience.org/library/papers/33782834PubMed
1325604744Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.J Antimicrob Chemother2015https://conductscience.org/library/papers/25604744PubMed
1430423057Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012-2016).Clin Infect Dis2018https://conductscience.org/library/papers/30423057PubMed
1517878146Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.J Antimicrob Chemother2007https://conductscience.org/library/papers/17878146PubMed
1628893690New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?Clin Microbiol Infect2017https://conductscience.org/library/papers/28893690PubMed
1723124906Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii.Infection2013https://conductscience.org/library/papers/23124906PubMed
1824566187In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.Antimicrob Agents Chemother2014https://conductscience.org/library/papers/24566187PubMed
1932184115Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations.Int J Antimicrob Agents2020https://conductscience.org/library/papers/32184115PubMed
2029800496Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients.Pharmacotherapy2018https://conductscience.org/library/papers/29800496PubMed

See all 61 referencesDownload CSV of references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
42712890A population pharmacokinetic model library for polymyxin B: clinical implementation of model-informed precision dosing.Front Pharmacol2026https://conductscience.org/library/papers/42712890PubMed
42582048Association of polymyxin B MIC with pharmacokinetic/pharmacodynamic target attainment and clinical outcomes in carbapenem-resistant enterobacterales infections.Front Pharmacol2026https://conductscience.org/library/papers/42582048PubMed
42489755Factors Affecting Pharmacokinetics and Dosing Strategies of Polymyxin B in Multidrug-resistant Gram-negative Infected Patients with Renal Impairment: A Systematic Review with Expert Opinion.Eur J Drug Metab Pharmacokinet2026https://conductscience.org/library/papers/42489755PubMed
42422069Can the two-point method based on peak and trough concentrations accurately estimate the area under the curve of polymyxin B? A Monte Carlo simulation study.Front Pharmacol2026https://conductscience.org/library/papers/42422069PubMed
42321962Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling.CPT Pharmacometrics Syst Pharmacol2026https://conductscience.org/library/papers/42321962PubMed
42243196Clinician decision-making for polymyxin dosing in critically ill patients with renal impairment: a qualitative study.Sci Rep2026https://conductscience.org/library/papers/42243196PubMed
41490412Safety and therapeutic potential evaluation of Cefotaxime plus Polymyxin B against polymyxin-carbapenem resistant Klebsiella pneumoniae in a murine model.PLoS One2026https://conductscience.org/library/papers/41490412PubMed
40906716Determining minimal inhibitory concentrations and antibiotic susceptibility for Enterobacterales by flow cytometry using reactive oxygen species as a marker.PLoS One2025https://conductscience.org/library/papers/40906716PubMed
40284021Biomarker-Driven Pharmacokinetics and Efficacy of Polymyxin B in Critically Ill Patients with XDR-GN Pneumonia.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40284021PubMed
40246790A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations.Clin Pharmacokinet2025https://conductscience.org/library/papers/40246790PubMed
40170884Aerosolized delivery resulting in high polymyxin B concentration levels in epithelial lining fluid ensures efficacy in ventilator-associated pneumonia.JAC Antimicrob Resist2025https://conductscience.org/library/papers/40170884PubMed
40078873Monte Carlo simulation to optimize polymyxin B dosing regimens for the treatment of Gram-negative bacteremia.Front Cell Infect Microbiol2025https://conductscience.org/library/papers/40078873PubMed
40047414
Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter study.
Antimicrob Agents Chemother2025https://conductscience.org/library/papers/40047414PubMed
39984645Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR.NPJ Antimicrob Resist2025https://conductscience.org/library/papers/39984645PubMed
39254296Synergistic antimicrobial combination of third-generation cephalosporins and polymyxin B against carbapenem-polymyxin-resistant Klebsiella pneumoniae: an in vitro and in vivo analysis.Antimicrob Agents Chemother2024https://conductscience.org/library/papers/39254296PubMed
39050834Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China.Infect Drug Resist2024https://conductscience.org/library/papers/39050834PubMed
38974043Polymyxins: recent advances and challenges.Front Pharmacol2024https://conductscience.org/library/papers/38974043PubMed
38847855How can polymyxin B be dosed based on current pharmacokinetic knowledge?Eur J Clin Pharmacol2024https://conductscience.org/library/papers/38847855PubMed
38483544Pharmacokinetics of polymyxin B in different populations: a systematic review.Eur J Clin Pharmacol2024https://conductscience.org/library/papers/38483544PubMed
38212555Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases.Infect Dis Ther2024https://conductscience.org/library/papers/38212555PubMed

See all 23 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GPT2875PubTator's text mininghttps://conductscience.org/library/genes/2875NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36588676

GET https://conductscience.org/api/papers/v1/36588676/references?page=2